PPARG and breast cancer: DMBA + ROSI cotreatment did not significantly change PPARγ-WT malignant mammary tumour incidence, but intriguingly, significantly increased malignant mammary tumour incidence by ~8-fold in PPARγ-MG KO mice (p < 0.01).